"L'Azienda Ospedale-Università di Padova (AOUP) è l’ospedale di riferimento della città di Padova. Con i suoi 1.682 posti letto (derivanti dall'acquisizione nel 2020 dell'Ospedale Sant'Antonio, con i suoi oltre 250 posti letto) è attualmente la più grande struttura ospedaliera d'Italia. Rappresenta un’eccellenza, a livello internazionale, per la cura di numerose malattie; è centro di riferimento per le Malattie Rare, oltre a importante polo di ricerca scientifica."

During the past decade, University Hospital of Padova conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 10 clinical trials were completed, i.e. on average, 27.8% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 9 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Hospital of Padova" #1 sponsor was "Celgene" with 8 trials, followed by "University of Padova" with 6 trials sponsored, "University Hospital Padova" with 4 trials sponsored, "Albireo" with 3 trials sponsored and "Galderma R&D" with 3 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Hospital of Padova" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Advance Research Associates" with 1 trials as a collaborator, "Azienda Ospedaliera di Padova" with 1 trials as a collaborator, "Azienda Ospedaliero-Universitaria Careggi, Firenze" with 1 trials as a collaborator and "CDI Centro Diagnostico Italiano" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "University Hospital of Padova" are "Crohn Disease" (4 trials), "Atrial Fibrillation" (2 trials), "Hematocrit Anemia" (2 trials), "Pain" (2 trials) and "Recurrent Low-grade Gliomas" (2 trials). Many other conditions were trialed in "University Hospital of Padova" in a lesser frequency.

Most popular intervention types in "University Hospital of Padova" are "Drug" (26 trials), "Procedure" (7 trials), "Other" (6 trials), "Device" (3 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Ozanimod" (3 trials), "A4250 (odevixibat)" (2 trials), "AG-221" (2 trials) and "Azacitidine" (2 trials). Other intervention names were less common.

The vast majority of trials in "University Hospital of Padova" are 44 trials for "All" genders.

Currently, there are NaN active trials in "University Hospital of Padova". undefined are not yet recruiting, 9 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in University Hospital of Padova, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in University Hospital of Padova, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 13 trials that are defined as “Not Applicable".